Skip to main content
. 2020 Apr 26;8(8):1361–1384. doi: 10.12998/wjcc.v8.i8.1361

Table 6.

Trials assessing the effect of VSL#3 in patients with cirrhosis

Ref. Design n VSL#3 intake
Gupta et al[127], 2013 RCT 94 with cirrhosis 2 mo with 9 × 1011 CFU a day
Jayakumar et al[129], 2013 RCT 17 with decompensated cirrhosis; 15 completed 2 mo with 3.6 × 1012 bacteria a day
Rincón et al[128], 2014 Not mentioned 17 with cirrhosis and ascites; 12 completed 6 wk, the dose was not clear
Marlicz et al[130], 2016 Not mentioned 20 with cirrhosis (13 with compensated liver cirrhosis, 7 with decompensated liver cirrhosis), and 10 healthy controls Daily for 28 d, the daily dose was not clear

RCT: Randomized controlled trial; CFU: Colony-forming unit.